PharmSci 360 to Convene in New Orleans This October
The American Association of Pharmaceutical Scientists will gather experts to discuss modern drug development paradigms.
Updated on Oct. 23, 2026 in Nutrition
Live Poll
Should regulatory agencies prioritize AI-based testing methods over traditional animal testing for new drugs?
The American Association of Pharmaceutical Scientists will host its 2026 PharmSci 360 meeting from October 25 to October 28, 2026, at the Ernest N. Morial Convention Center in New Orleans. The event focuses on redesigning the drug development process to improve efficiency while maintaining quality.
Why it matters
The meeting addresses the industry shift toward accelerated drug development timelines and emerging methodology standards. Leaders will explore integrated approaches, including the integration of new testing models following recent regulatory changes.
AAPS supports over 7,000 members and publishes four peer-reviewed journals. The meeting includes a 2.5-day workshop focused on complex generics and quality standards.
The players
Dr. Julie Louise Gerberding
She serves as the president and CEO of the Foundation for the National Institutes of Health.
American Association of Pharmaceutical Scientists
This professional organization consists of over 7,000 members focused on pharmaceutical science and publishes four peer-reviewed journals.
Thomas Hartung
He is a researcher scheduled to lead a track on new testing approaches during the conference.
Brian Nosek
He is a contributor scheduled to lead a conference track regarding research credibility.
Patrick J. Sinko
He holds the position of chief science officer for the American Association of Pharmaceutical Scientists.
The details
Dr. Julie Louise Gerberding will open the conference with a plenary address centered on increasing efficiency in the drug development pipeline. The schedule includes a track on new testing approaches, building on an April 10, 2025, FDA plan to reduce animal testing requirements for certain drug types.
Timeline
April 10, 2025: The FDA announces a plan to phase out animal testing for monoclonal antibodies.
October 25, 2026: The PharmSci 360 meeting begins in New Orleans.
October 26, 2026: Brian Nosek leads a track dedicated to research credibility.
October 26-28, 2026: A joint AAPS-USP workshop on complex generics takes place.
October 28, 2026: Thomas Hartung leads a track on testing approaches and the closing plenary.
Health Landscape
This conference aligns with the FDA plan to phase out animal testing requirements for monoclonal antibodies and other drugs. The event marks a broader transition toward computational models and organoids in medical research.
The transition to new testing methodologies, such as AI-based models, aims to streamline the development of new medications for patients. These shifts could eventually lead to faster access to novel treatments by reducing the time required for drug quality validation.
The takeaway
The conference highlights the industry's commitment to evolving beyond legacy testing methods to improve development timelines. Attendees will focus on how integrated paradigms can maintain rigorous quality standards while embracing technological advancements.
Further reading
Learn more about the latest developments in health at New Orleans Nutrition.
Source note: This article includes information reported by BioPharm International.
Live Poll
Should regulatory agencies prioritize AI-based testing methods over traditional animal testing for new drugs?
